Logo Logo
Hilfe
Hilfe
Switch Language to English

Hegele, Robert A.; Boren, Jan; Ginsberg, Henry N.; Arca, Marcello; Averna, Maurizio; Binder, Christoph J.; Calabresi, Laura; Chapman, M. John; Cuchel, Marina; Eckardstein, Arnold von; Frikke-Schmidt, Ruth; Gaudet, Daniel; Hovingh, G. Kees; Kronenberg, Florian; Luetjohann, Dieter; Parhofer, Klaus G.; Raal, Frederick J.; Ray, Kausik K.; Remaley, Alan T.; Stock, Jane K.; Stroes, Erik S.; Tokgozoglu, Lale und Catapano, Alberico L. (2020): Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. In: Lancet Diabetes & Endocrinology, Bd. 8, Nr. 1: S. 50-67

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Genome sequencing and gene-based therapies appear poised to advance the management of rare lipoprotein disorders and associated dyslipidaemias. However, in practice, underdiagnosis and undertreatment of these disorders are common, in large part due to interindividual variability in the genetic causes and phenotypic presentation of these conditions. To address these challenges, the European Atherosclerosis Society formed a task force to provide practical dinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. The task force also recognises the scarcity of quality information regarding the prevalence and outcomes of these conditions. Collaborative registries are needed to improve health policy for the care of patients with rare dyslipidaemias.

Dokument bearbeiten Dokument bearbeiten